Hemocompatibility Assessment of two siRNA Nanocarrier Formulations

Abstract

Taken together, these in vitro assays may help the selection of suitable carriers for systemic delivery of siRNA in early preclinical investigations and reduce the use of laboratory animals significantly.

Preclinical evaluation of thermosensitive poly(N-(2-hydroxypropyl) methacrylamide mono/dilactate)-grafted liposomes for cancer thermochemotherapy

“…Blood was drawn from healthy volunteers into citrate-containing Vacutainer tubes (BD Biosciences, Franklin Lakes, NJ). Platelets were isolated according to a previously described method (Korporaal et al, 2007;Yousefi et al, 2014). Blood was centrifuged at 160×g for 15 min at room temperature (RT) to obtain platelet-rich plasma (PRP).…”

“…The liposomes (150 µM final phospholipid concentration) were mixed with APC-anti-GP1B (25:1), FITC-anti-fibrinogen (25:1), and PE-anti-P-selectin (12.5:1). TRAP-6, a strong platelet activator (Yousefi et al, 2014), was used as a positive control (208 µM final concentration). The mixtures were incubated at 37 °C for 30 min prior to use, after which 10 µL of isolated platelets or whole blood was added and incubated for 20 min at RT.…”

Synthetic nanocarriers for the delivery of polynucleotides to the eye

“…In the particular case of the eye, interaction with melanin may alter the PK profile of the drug in the eye generating locally high concentration of the drug upon release from melanin (Agrahari et al, 2016). Formulations reaching the bloodstream may also potentially interact with components of the complement system or coagulation inducing side effects (Yousefi et al, 2014). The assessment of these toxicities is not necessarily straightforward as animal models are not necessarily good predictors of human immune systems.…”